Evidence map›Paper›PMID 34602092›Full record

ArticleAnnals of clinical microbiology and antimicrobials2021

Francisella philomiragia bacteremia in an immunocompromised patient: a rare case report.

Hui Shan Chua, Yih Harng Soh, Shih Keng Loong, Sazaly AbuBakar

Open access · goldAbstract readCase Reports
In one paragraph

Article in Annals of clinical microbiology and antimicrobials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Genetically divergentNew microbes and new infections · 2024
    Article
  2. Functional characterization ofFrontiers in cellular and infection microbiology · 2024
    Article
  3. Case report:Frontiers in cellular and infection microbiology · 2023
    Article
  4. Article
  5. Treatment of Francisella philomiragia bacteremia in a dog.Journal of veterinary internal medicine
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Hui Shan ChuaDepartment of Pathology, Hospital Melaka, Jalan Mufti Haji Khalil, 75400, Melaka, Malaysia.
Yih Harng SohUnit of Infection Control, Hospital Melaka, Jalan Mufti Haji Khalil, 75400, Melaka, Malaysia. snoopy84@gmail.com.ORCID http://orcid.org/0000-0003-1239-5903
Shih Keng LoongTropical Infectious Diseases Research & Education Centre (TIDREC), High Impact Research Building, Universiti Malaya, 50603, Kuala Lumpur, Malaysia. loongsk@um.edu.my.
Sazaly AbuBakarTropical Infectious Diseases Research & Education Centre (TIDREC), High Impact Research Building, Universiti Malaya, 50603, Kuala Lumpur, Malaysia.
Malacca General Hospital · MYUniversity Malaya Medical Centre · MYUniversity of Malaya · MY

Funding

um research university grant-tropical infectious diseases programme RU002-2019um research university grant-tropical infectious diseases programme RU005-2020
6 · The paper itself

Abstract

backgroundFrancisella philomiragia is a very rare opportunistic pathogen of humans which causes protean diseases such as pneumonia and other systemic infections. Subsequent failure of prompt treatment may result in poor prognosis with mortality among infected patients. CASE PRESENTATION: The present report describes a case of F. philomiragia bacteraemia first reported in Malaysia and Asian in a 60-year-old patient with underlying end-stage renal disease (ESRF) and diabetes mellitus. He presented with Acute Pulmonary Oedema with Non-ST-Elevation Myocardial Infarction (NSTEMI) in our hospital. He was intubated in view of persistent type I respiratory failure and persistent desaturation despite post haemodialysis. Blood investigation indicated the presence of ongoing infection and inflammation. The aerobic blood culture growth of F. philomiragia was identified using the matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry (Score value: 2.16) and confirmed by 16S Ribosomal DNA (16S rDNA) sequencing. He was discharged well on day 26 of admission, after completing one week of piperacillin/tazobactam and two weeks of doxycycline.

conclusionClinical suspicion should be raised if patients with known risk factors are presenting with pneumonia or pulmonary nodules especially as these are the most common manifestations of F. philomiragia infection. Early diagnosis via accurate laboratory identification of the organism through MALDI-TOF mass spectrometry and molecular technique such as 16S rDNA sequencing are vital for prompt treatment that results in better outcomes for the afflicted patients.

Indexed as

BacteremiaDiabetes Mellitus, Type 2DNA, RibosomalFrancisellaGram-Negative Bacterial InfectionsHumansImmunocompromised HostKidney Failure, ChronicMaleMiddle AgedNon-ST Elevated Myocardial InfarctionPulmonary EdemaSepsisSequence Analysis, DNASpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationDNA, Ribosomal16S rDNAFrancisella philomiragiaInfectious diseaseMalaysiaMALDI-TOFPneumonia

Identifiers

PMID34602092
PMCPMC8489096
OpenAlexW3202302781

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.